Ann: Plan to Pursue Re-domiciliation, Nasdaq listing and US IPO, page-5

Very happy.

My own current valuation of the Anteris technologies, ADAPT, DurAVR and TMVR (which I have ascribed a $0 value to although am expecting to grow significantly over next few years) is in the $US Billions..... It has been very frustrating for me to see the lack of recognition given to the technologies worth here in Australia and I believe this will change when/if we enter the US.

The DurAVR represents a once in a generation medical technology.... it will very likely end up earning (whoever brings it to market) tens of US$Billions. It is an EXTREMELY valuable asset, yet is not treated as such by Australian investors. This change in geography will be a good thing.